News
China’s New Cancer drug is Approved in the US But Will Cost 30 Times More

(CTN News) – Two other cancer medications created by Chinese scientists are also expected to face price increases in the US market, with one drug costing more than 30 times more than in China. The FDA just authorized the drug.
Chinese cancer medications will be priced much lower than American equivalents, even after accounting for the enormous markup in the US market.
The pricing of Loqtorzi, the US brand name for Toripalimab, was released on Monday by California-based Coherus Biosciences and Shanghai Junshi Biosciences, the drug’s marketing partners.
According to Chinese cancer informational websites, the cost of a single-dose vial of Toripalimab is approximately 2,000 yuan (US$280) in China.
In a Monday filing to the US Securities and Exchange Commission, Coherus announced that the wholesale cost of a single-dose vial in the US will be $8,892.03. Compared to the same drug sold in China, the price in the US is over 31 times higher.
Even with the price increase, FiercePharma estimates it will be 20% cheaper than Keytruda, the best-selling PD-1 antibody medication in the US. PD-1 inhibitors help keep the immune system in balance.
The drug’s retail price in China is different from its national healthcare insurance enrollment price.
National Medical Insurance Administration data shows that by year’s end, nearly all Chinese citizens (95 percent) had enrolled in the system and gained basic coverage.
Like the black market for cocaine, the drug price has skyrocketed. According to US media, the street value in the US is forty times higher than in Colombia, the drug’s country of origin.
This month, the FDA approved two additional cancer medications developed in China for distribution in the US, after Toripalimab’s clearance.
The Chinese biotech company HutchMed’s oral medicine fruquintinib was approved for the treatment of persons with metastatic colorectal cancer who have already received treatment for the disease on November 9.
To treat chemotherapy-induced neutropenia, or low levels of a type of white blood cells, Evive Biotech—a worldwide biopharma subsidiary of Yifan Pharmaceutical based in Hangzhou—developed the injectable medication efbemalenograstim alfa. On November 16, the drug was approved for use.
Just as Toripalimab, fruquintinib—which will be sold in the US by the Tokyo-based Takeda Pharmaceutical Company under the brand name Fruzaqla—will also experience a price increase.
According to Medical Valley, a Chinese medical news site, a box of 21 pills containing 5mg of the medicine is offered in China for approximately 7,500 yuan (US$1,050). The identical dosage, according to a Takeda prescription, will cost $25,200 at wholesale in the United States, which is twenty-four times more than the cost in China.
A study released last year in the Journal of the American Medical Association cast doubt on the assertion made by US pharma corporations that the high cost of research and development is the driving force behind the country’s medicine prices.
In spite of the fact that the United States pays the most for innovative pharmaceuticals, the study found that the government health insurance program in the nation has never been able to negotiate lower rates.
From 2009 to 2018, the authors examined 60 medications, or 20% of all drugs approved. They discovered no correlation between the reported prices of these treatments and their estimated research expenses.
The study concluded that drug corporations set their prices based on market demand. This is affected by the drug’s demand, whether patients need to take it continually, and the market competition level.
After Toripalimab’s approval, many wondered if the medicine would be sold at a steep discount compared to its primary US market rival.
This ensued after pharmaceutical behemoth Eli Lilly made a 40% discount promise for their Chinese PD-1 drug that they were requesting FDA clearance for.
However, as reported by FiercePharma, Coherus CEO Dennis Lanfear stated on an investor call following Toripalimab’s approval that such a “heavily” discounted price was not being considered.
According to FiercePharma, Keytruda, the major competitor to Toripalimab available in China, was listed at half the price it is in the US when it first entered the market. Merck & Co. is situated in New Jersey.
Fruquintinib, an oral medicine, is the first chemotherapy-free treatment option for individuals with metastatic colorectal cancer in more than ten years. It is prescribed to patients with advanced stages of the disease. The NMPA, China’s national medical products agency, gave its initial green light to it in 2018.
The American Cancer Society reports that colorectal cancer, which starts in the colon or rectum, is the third most frequent cancer in the United States and the third greatest cause of cancer-related deaths for both men and women. According to a news release from Takeda regarding the medicine, colorectal cancer was ranked third globally.
“There has been limited innovation for patients with metastatic colorectal cancer for more than a decade,” stated Teresa Bitetti, president of global oncology business at Takeda.
Colorectal cancer is responsible for 7.8% of all new cancer diagnoses in the United States. Takeda reports that 70% of colorectal cancer patients will have metastasis, which occurs when malignant growths extend beyond the colon and rectum.
According to Cathy Eng, a doctor at Vanderbilt University Medical Centre, “metastatic cancer patients often present with inoperable disease… we must evaluate and consider treatment options that will improve overall survival without compromising quality of life” (hutchMed, 2019).
Fruquintinib was approved after two trials that included over 1,000 individuals. Patients in the studies who received both the medicine and supportive care had twice the progression-free survival rate than those who received only supportive care or a placebo.
Takeda reported a 34% reduction in mortality risk in patients treated with Fruquintinib. The Food and Drug Administration reported that hypertension was the medication’s most common side effect, followed by hand-foot syndrome and increased protein in the urine.
Other businesses own the rights to sell the three Chinese medications that the FDA approved this month in the US.
According to HutchMed, they will get royalties on net sales and other payments if the drug hits major milestones, while Takeda will manufacture and commercialize Fruquintinib outside of China.
Acrotech Biopharma of New Jersey claims that its drug efbemalenograstim alfa, which will be sold in the United States under the brand name Ryzneuta, can help avoid the negative effects of low neutrophil numbers.
Patients are more likely to get infections when their neutrophil count is low; the CDC reports that chemotherapy-induced neutrophil count drops often occur in the weeks following treatment.
Acrotech reported that the medicine, licensed by the NMPA in May in China, has been tested in 12 clinical trials with over 1,200 patients worldwide. The results show that the treatment effectively reduces the time patients spend with extremely low neutrophil levels.
Biotech company BeiGene co-founder Wang Xiaodong predicted earlier this month at the Hong Kong Laureate Forum that China will spearhead an explosion in the study of novel medications.
As far as the West is concerned, China is already well ahead. “Chinese companies will produce even more of a product if it is available overseas,” Wang stated.

News
Google’s Search Dominance Is Unwinding, But Still Accounting 48% Search Revenue

Google is so closely associated with its key product that its name is a verb that signifies “search.” However, Google’s dominance in that sector is dwindling.
According to eMarketer, Google will lose control of the US search industry for the first time in decades next year.
Google will remain the dominant search player, accounting for 48% of American search advertising revenue. And, remarkably, Google is still increasing its sales in the field, despite being the dominating player in search since the early days of the George W. Bush administration. However, Amazon is growing at a quicker rate.
Google’s Search Dominance Is Unwinding
Amazon will hold over a quarter of US search ad dollars next year, rising to 27% by 2026, while Google will fall even more, according to eMarketer.
The Wall Street Journal was first to report on the forecast.
Lest you think you’ll have to switch to Bing or Yahoo, this isn’t the end of Google or anything really near.
Google is the fourth-most valued public firm in the world. Its market worth is $2.1 trillion, trailing just Apple, Microsoft, and the AI chip darling Nvidia. It also maintains its dominance in other industries, such as display advertisements, where it dominates alongside Facebook’s parent firm Meta, and video ads on YouTube.
To put those “other” firms in context, each is worth more than Delta Air Lines’ total market value. So, yeah, Google is not going anywhere.
Nonetheless, Google faces numerous dangers to its operations, particularly from antitrust regulators.
On Monday, a federal judge in San Francisco ruled that Google must open up its Google Play Store to competitors, dealing a significant blow to the firm in its long-running battle with Fortnite creator Epic Games. Google announced that it would appeal the verdict.
In August, a federal judge ruled that Google has an illegal monopoly on search. That verdict could lead to the dissolution of the company’s search operation. Another antitrust lawsuit filed last month accuses Google of abusing its dominance in the online advertising business.
Meanwhile, European regulators have compelled Google to follow tough new standards, which have resulted in multiple $1 billion-plus fines.

Pixa Bay
Google’s Search Dominance Is Unwinding
On top of that, the marketplace is becoming more difficult on its own.
TikTok, the fastest-growing social network, is expanding into the search market. And Amazon has accomplished something few other digital titans have done to date: it has established a habit.
When you want to buy anything, you usually go to Amazon, not Google. Amazon then buys adverts to push companies’ products to the top of your search results, increasing sales and earning Amazon a greater portion of the revenue. According to eMarketer, it is expected to generate $27.8 billion in search revenue in the United States next year, trailing only Google’s $62.9 billion total.
And then there’s AI, the technology that (supposedly) will change everything.
Why search in stilted language for “kendall jenner why bad bunny breakup” or “police moving violation driver rights no stop sign” when you can just ask OpenAI’s ChatGPT, “What’s going on with Kendall Jenner and Bad Bunny?” in “I need help fighting a moving violation involving a stop sign that wasn’t visible.” Google is working on exactly this technology with its Gemini product, but its success is far from guaranteed, especially with Apple collaborating with OpenAI and other businesses rapidly joining the market.
A Google spokeswoman referred to a blog post from last week in which the company unveiled ads in its AI overviews (the AI-generated text that appears at the top of search results). It’s Google’s way of expressing its ability to profit on a changing marketplace while retaining its business, even as its consumers steadily transition to ask-and-answer AI and away from search.
Google has long used a single catchphrase to defend itself against opponents who claim it is a monopoly abusing its power: competition is only a click away. Until recently, that seemed comically obtuse. Really? We are going to switch to Bing? Or Duck Duck Go? Give me a break.
But today, it feels more like reality.
Google is in no danger of disappearing. However, every highly dominating company faces some type of reckoning over time. GE, a Dow mainstay for more than a century, was broken up last year and is now a shell of its previous dominance. Sears declared bankruptcy in 2022 and is virtually out of business. US Steel, long the foundation of American manufacturing, is attempting to sell itself to a Japanese corporation.
SOURCE | CNN
News
The Supreme Court Turns Down Biden’s Government Appeal in a Texas Emergency Abortion Matter.

(VOR News) – A ruling that prohibits emergency abortions that contravene the Supreme Court law in the state of Texas, which has one of the most stringent abortion restrictions in the country, has been upheld by the Supreme Court of the United States. The United States Supreme Court upheld this decision.
The justices did not provide any specifics regarding the underlying reasons for their decision to uphold an order from a lower court that declared hospitals cannot be legally obligated to administer abortions if doing so would violate the law in the state of Texas.
Institutions are not required to perform abortions, as stipulated in the decree. The common populace did not investigate any opposing viewpoints. The decision was made just weeks before a presidential election that brought abortion to the forefront of the political agenda.
This decision follows the 2022 Supreme Court ruling that ended abortion nationwide.
In response to a request from the administration of Vice President Joe Biden to overturn the lower court’s decision, the justices expressed their disapproval.
The government contends that hospitals are obligated to perform abortions in compliance with federal legislation when the health or life of an expectant patient is in an exceedingly precarious condition.
This is the case in regions where the procedure is prohibited. The difficulty hospitals in Texas and other states are experiencing in determining whether or not routine care could be in violation of stringent state laws that prohibit abortion has resulted in an increase in the number of complaints concerning pregnant women who are experiencing medical distress being turned away from emergency rooms.
The administration cited the Supreme Court’s ruling in a case that bore a striking resemblance to the one that was presented to it in Idaho at the beginning of the year. The justices took a limited decision in that case to allow the continuation of emergency abortions without interruption while a lawsuit was still being heard.
In contrast, Texas has been a vocal proponent of the injunction’s continued enforcement. Texas has argued that its circumstances are distinct from those of Idaho, as the state does have an exemption for situations that pose a significant hazard to the health of an expectant patient.
According to the state, the discrepancy is the result of this exemption. The state of Idaho had a provision that safeguarded a woman’s life when the issue was first broached; however, it did not include protection for her health.
Certified medical practitioners are not obligated to wait until a woman’s life is in imminent peril before they are legally permitted to perform an abortion, as determined by the state supreme court.
The state of Texas highlighted this to the Supreme Court.
Nevertheless, medical professionals have criticized the Texas statute as being perilously ambiguous, and a medical board has declined to provide a list of all the disorders that are eligible for an exception. Furthermore, the statute has been criticized for its hazardous ambiguity.
For an extended period, termination of pregnancies has been a standard procedure in medical treatment for individuals who have been experiencing significant issues. It is implemented in this manner to prevent catastrophic outcomes, such as sepsis, organ failure, and other severe scenarios.
Nevertheless, medical professionals and hospitals in Texas and other states with strict abortion laws have noted that it is uncertain whether or not these terminations could be in violation of abortion prohibitions that include the possibility of a prison sentence. This is the case in regions where abortion prohibitions are exceedingly restrictive.
Following the Supreme Court’s decision to overturn Roe v. Wade, which resulted in restrictions on the rights of women to have abortions in several Republican-ruled states, the Texas case was revisited in 2022.
As per the orders that were disclosed by the administration of Vice President Joe Biden, hospitals are still required to provide abortions in cases that are classified as dire emergency.
As stipulated in a piece of health care legislation, the majority of hospitals are obligated to provide medical assistance to patients who are experiencing medical distress. This is in accordance with the law.
The state of Texas maintained that hospitals should not be obligated to provide abortions throughout the litigation, as doing so would violate the state’s constitutional prohibition on abortions. In its January judgment, the 5th United States Circuit Court of Appeals concurred with the state and acknowledged that the administration had exceeded its authority.
SOURCE: AP
SEE ALSO:
Could Last-Minute Surprises Derail Kamala Harris’ Campaign? “Nostradamus” Explains the US Poll.
News
Supreme Court Rejects Appeal From ‘Pharma Bro’ Martin Shkreli, To repay $6.4 Million

Washington — The Supreme Court rejected Martin Shkreli’s appeal on Monday, after he was branded “Pharma Bro” for raising the price of a lifesaving prescription.
Martin appealed a decision to repay $64.6 million in profits he and his former company earned after monopolizing the pharmaceutical market and dramatically raising its price. His lawyers claimed the money went to his company rather than him personally.
The justices did not explain their reasoning, as is customary, and there were no notable dissents.
Prosecutors, conversely, claimed that the firm had promised to pay $40 million in a settlement and that because Martin orchestrated the plan, he should be held accountable for returning profits.
Supreme Court Rejects Appeal From ‘Pharma Bro’ Martin Shkreli
Martin was also forced to forfeit the Wu-Tang Clan’s unreleased album “Once Upon a Time in Shaolin,” which has been dubbed the world’s rarest musical album. The multiplatinum hip-hop group auctioned off a single copy of the record in 2015, stipulating that it not be used commercially.
Shkreli was convicted of lying to investors and defrauding them of millions of dollars in two unsuccessful hedge funds he managed. Shkreli was the CEO of Turing Pharmaceuticals (later Vyera), which hiked the price of Daraprim from $13.50 to $750 per pill after acquiring exclusive rights to the decades-old medicine in 2015. It cures a rare parasite condition that affects pregnant women, cancer patients, and HIV patients.
He defended the choice as an example of capitalism in action, claiming that insurance and other programs ensured that those in need of Daraprim would eventually receive it. However, the move prompted criticism, from the medical community to Congress.
Supreme Court Rejects Appeal From ‘Pharma Bro’ Martin Shkreli
Attorney Thomas Huff said the Supreme Court’s Monday ruling was upsetting, but the high court could still overturn a lower court judgment that allowed the $64 million penalty order even though Shkreli had not personally received the money.
“If and when the Supreme Court does so, Mr. Shkreli will have a strong argument for modifying the order accordingly,” he told reporters.
Shkreli was freed from prison in 2022 after serving most of his seven-year sentence.
SOURCE | AP
-
News4 years ago
Let’s Know About Ultra High Net Worth Individual
-
Entertainment2 years ago
Mabelle Prior: The Voice of Hope, Resilience, and Diversity Inspiring Generations
-
Health4 years ago
How Much Ivermectin Should You Take?
-
Tech2 years ago
Top Forex Brokers of 2023: Reviews and Analysis for Successful Trading
-
Lifestyles3 years ago
Aries Soulmate Signs
-
Movies2 years ago
What Should I Do If Disney Plus Keeps Logging Me Out of TV?
-
Health3 years ago
Can I Buy Ivermectin Without A Prescription in the USA?
-
Learning3 years ago
Virtual Numbers: What Are They For?